Literature DB >> 6784807

Human insulin: study of safety and efficacy in man.

D R Owens, M K Jones, T M Hayes, L G Heding, K G Alberti, P D Home, J M Burrin, R G Newcombe.   

Abstract

The safety and efficacy of a new highly purified neutral soluble human insulin produced by conversion of porcine insulin was compared with a highly purified neutral soluble porcine insulin in six normal men. The insulins were administered by subcutaneous injection at a dose of 0.075 U/kg body weight. Somatostatin was infused during the experiment to suppress endogenous insulin secretin. No difference was found in the plasma glucose, insulin, or metabolite responses. Thus the potency, onset, and duration of effect were identical with the two insulins. No short-term side effects to either insulin were observed. Highly purified, semi-synthetic human insulin offers a safe and effective means to explore the possible advantages of homologous human insulin in the management of diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6784807      PMCID: PMC1505391          DOI: 10.1136/bmj.282.6272.1264

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  14 in total

1.  Somatostatin and diabetes: suppression of glucose absorption rather than stimulation of glucose disposal.

Authors:  P Felig; J Wahren
Journal:  Metabolism       Date:  1976-11       Impact factor: 8.694

2.  Semi-synthesis of human insulin by trypsin-catalysed replacement of Ala-B30 by Thr in porcine insulin.

Authors:  K Morihara; T Oka; H Tsuzuki
Journal:  Nature       Date:  1979-08-02       Impact factor: 49.962

3.  [Total synthesis of human insulin under directed formation of the disulfide bonds].

Authors:  P Sieber; B Kamber; A Hartmann; A Jöhl; B Riniker; W Rittel
Journal:  Helv Chim Acta       Date:  1974       Impact factor: 2.164

4.  Inhibition of insulin secretion by somatostatin.

Authors:  K G Alberti; N J Christensen; S E Christensen; A P Hansen; J Iversen; K Lundbaek; K Seyer-Hansen; H Orskov
Journal:  Lancet       Date:  1973-12-08       Impact factor: 79.321

5.  Determination of total serum insulin (IRI) in insulin-treated diabetic patients.

Authors:  L G Heding
Journal:  Diabetologia       Date:  1972-08       Impact factor: 10.122

6.  Blood intermediary metabolite and insulin concentrations after an overnight fast: reference ranges for adults, and interrelations.

Authors:  K J Foster; K G Alberti; L Hinks; B Lloyd; A Postle; P Smythe; D C Turnell; R Walton
Journal:  Clin Chem       Date:  1978-09       Impact factor: 8.327

7.  Radioimmunological determination of human C-peptide in serum.

Authors:  L G Heding
Journal:  Diabetologia       Date:  1975-12       Impact factor: 10.122

8.  [The biological effect of purely synthetic human insulin in patients with diabetes mellitus].

Authors:  A Teuscher
Journal:  Schweiz Med Wochenschr       Date:  1979-05-19

9.  [Somatostatin, a new hormone? (author's transl)].

Authors:  R Assan
Journal:  Diabete Metab       Date:  1976-09

10.  Enzymic fluorometric continuous-flow assays for blood glucose, lactate, pyruvate, alanine, glycerol, and 3-hydroxybutyrate.

Authors:  B Lloyd; J Burrin; P Smythe; K G Alberti
Journal:  Clin Chem       Date:  1978-10       Impact factor: 8.327

View more
  8 in total

1.  Human insulin.

Authors:  P Home
Journal:  Br Med J (Clin Res Ed)       Date:  1986-03-01

2.  Biological potency of porcine, bovine and human insulins in the rabbit bioassay system.

Authors:  M Pingel; A Vølund; E Sørensen; J E Collins; C T Dieter
Journal:  Diabetologia       Date:  1985-11       Impact factor: 10.122

3.  Comparison of human and porcine insulin therapies in children with newly diagnosed diabetes mellitus.

Authors:  K Zuppinger; C Aebi; S Fankhauser; G Herz; R P Zurbrügg; K Schopfer; T M Neri
Journal:  Diabetologia       Date:  1987-12       Impact factor: 10.122

4.  Repeatability and reproducibility of the hyperinsulinemic-euglycemic clamp and the tracer dilution technique in a controlled inpatient setting.

Authors:  Duc Son N T Le; Thomas Brookshire; Jonathan Krakoff; Joy C Bunt
Journal:  Metabolism       Date:  2009-03       Impact factor: 8.694

5.  Circadian profiles of blood glucose and plasma free insulin during treatment with semisynthetic and biosynthetic human insulin, and comparison with conventional monocomponent preparations.

Authors:  M Castillo; A Nemery; E Verdin; P J Lefebvre; A S Luyckx
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

6.  A comparison of the activity and disposal of semi-synthetic human insulin and porcine insulin in normal man by the glucose clamp technique.

Authors:  P D Home; M Massi-Benedetti; G A Shepherd; I Hanning; K G Alberti; D R Owens
Journal:  Diabetologia       Date:  1982-01       Impact factor: 10.122

Review 7.  The new insulins. Their characteristics and clinical indications.

Authors:  P D Home; K G Alberti
Journal:  Drugs       Date:  1982-11       Impact factor: 9.546

8.  Semisynthetic human insulin and purified pork insulin do not differ in their biological potency.

Authors:  P Arias; W Kerner; I Navascués; G Schäfauer; E F Pfeiffer
Journal:  Klin Wochenschr       Date:  1984-12-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.